TY - JOUR
T1 - Mucus reduction promotes acetyl salicylic acid-induced small intestinal mucosal injury in rats
AU - Suyama, Yosuke
AU - Handa, Osamu
AU - Naito, Yuji
AU - Takayama, Shun
AU - Mukai, Rieko
AU - Ushiroda, Chihiro
AU - Majima, Atsushi
AU - Yasuda-Onozawa, Yuriko
AU - Higashimura, Yasuki
AU - Fukui, Akifumi
AU - Dohi, Osamu
AU - Okayama, Tetsuya
AU - Yoshida, Naohisa
AU - Katada, Kazuhiro
AU - Kamada, Kazuhiro
AU - Uchiyama, Kazuhiko
AU - Ishikawa, Takeshi
AU - Takagi, Tomohisa
AU - Konishi, Hideyuki
AU - Itoh, Yoshito
N1 - Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/3/25
Y1 - 2018/3/25
N2 - Background: Acetyl salicylic acid (ASA) is a useful drug for the secondary prevention of cerebro-cardiovascular diseases, but it has adverse effects on the small intestinal mucosa. The pathogenesis and prophylaxis of ASA-induced small intestinal injury remain unclear. In this study, we focused on the intestinal mucus, as the gastrointestinal tract is covered by mucus, which exhibits protective effects against various gastrointestinal diseases. Materials and Methods: ASA was injected into the duodenum of rats, and small intestinal mucosal injury was evaluated using Evans blue dye. To investigate the importance of mucus, Polysorbate 80 (P80), an emulsifier, was used before ASA injection. In addition, rebamipide, a mucus secretion inducer in the small intestine, was used to suppress mucus reduction in the small intestine of P80-administered rats. Results: The addition of P80 reduced the mucus and exacerbated the ASA-induced small intestinal mucosal injury. Rebamipide significantly suppressed P80-reduced small intestinal mucus and P80-increased intestinal mucosal lesions in ASA-injected rats, demonstrating that mucus is important for the protection against ASA-induced small intestinal mucosal injury. These results provide new insight into the mechanism of ASA-induced small intestinal mucosal injury. Conclusion: Mucus secretion-increasing therapy might be useful in preventing ASA-induced small intestinal mucosal injury.
AB - Background: Acetyl salicylic acid (ASA) is a useful drug for the secondary prevention of cerebro-cardiovascular diseases, but it has adverse effects on the small intestinal mucosa. The pathogenesis and prophylaxis of ASA-induced small intestinal injury remain unclear. In this study, we focused on the intestinal mucus, as the gastrointestinal tract is covered by mucus, which exhibits protective effects against various gastrointestinal diseases. Materials and Methods: ASA was injected into the duodenum of rats, and small intestinal mucosal injury was evaluated using Evans blue dye. To investigate the importance of mucus, Polysorbate 80 (P80), an emulsifier, was used before ASA injection. In addition, rebamipide, a mucus secretion inducer in the small intestine, was used to suppress mucus reduction in the small intestine of P80-administered rats. Results: The addition of P80 reduced the mucus and exacerbated the ASA-induced small intestinal mucosal injury. Rebamipide significantly suppressed P80-reduced small intestinal mucus and P80-increased intestinal mucosal lesions in ASA-injected rats, demonstrating that mucus is important for the protection against ASA-induced small intestinal mucosal injury. These results provide new insight into the mechanism of ASA-induced small intestinal mucosal injury. Conclusion: Mucus secretion-increasing therapy might be useful in preventing ASA-induced small intestinal mucosal injury.
UR - http://www.scopus.com/inward/record.url?scp=85042850635&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042850635&partnerID=8YFLogxK
U2 - 10.1016/j.bbrc.2018.02.202
DO - 10.1016/j.bbrc.2018.02.202
M3 - Article
C2 - 29501492
AN - SCOPUS:85042850635
SN - 0006-291X
VL - 498
SP - 228
EP - 233
JO - Biochemical and Biophysical Research Communications
JF - Biochemical and Biophysical Research Communications
IS - 1
ER -
